content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Asterias Biotherapeutics (AST)

3.35
0.10
(3.08%)
Sep 11, 4:00PM EDT
content_middle

Asterias Biotherapeutics (ASTY), a spin-out of BioTime (NYSEMKT: BTX) <acquired the cell therapy assets of Geron>.  AST  is working to re-initiate clinical trials of AST-OPC1 (OPC1) , the first human embryonic stem cell (hESC)-derived product to enter human clinical testing for spinal cord injury, and is preparing a 2nd trial of hESC-derived dendritic cells for lung cancer. ASTY has a portfolio of over 400 issued patents and patent applications. 

Previous Close: 
3.25
Open: 
3.20
Bid: 
2.95
Ask: 
3.85
1yr Target Price: 
10.15
Day's Range: 
3.20 - 3.35
52wk Range: 
2.83 - 5.80
Volume: 
160265
Average Daily Volume: 
111902
Market Capitalization: 
167.43M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
49978000M
content_right

Pages